VAXX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States...

Stats
Today's Volume	1.93M
Average Volume	696 012
Market Cap	14.78M
EPS	$0 ( 2024-03-25 )
Next earnings date	( $-0.100 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.260
ATR14	$0.00100 (0.85%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-03	Paula Molina Rene	Buy	0
2023-10-02	Powchik Peter	Buy	159 744	Stock option (right to buy)
2023-10-01	Ray Sumita	Buy	0
2023-09-06	Prime Movers Lab Fund I Lp	Sell	5 308	Class A Common Stock
2023-09-07	Prime Movers Lab Fund I Lp	Sell	20 312	Class A Common Stock

INSIDER POWER
49.31
Last 91 transactions
Buy: 5 925 518 \| Sell: 2 685 509

Volume Correlation

Long: -0.07 (neutral)

Short: -0.48 (neutral)

Signal:(62.509) Neutral

Vaxxinity, Inc. Correlation

10 Most Positive Correlations
MEUSW	0.894
VYGR	0.876
ADXN	0.863
LIAN	0.855
IMAB	0.852
WWD	0.85
HSDT	0.849
ICUI	0.848
PXLW	0.845
PRAX	0.84

10 Most Negative Correlations
MTSL	-0.822
EA	-0.815

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vaxxinity, Inc. Correlation - Currency/Commodity

0.00
( neutral )

0.17
( neutral )

Vaxxinity, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.23M (0.00 %)
EPS:	$-0.450

FY	2023
Revenue:	$0
Gross Profit:	$-2.23M (0.00 %)
EPS:	$-0.450

FY	2022
Revenue:	$0
Gross Profit:	$-1.68M (0.00 %)
EPS:	$-0.600

FY	2021
Revenue:	$66 000.00
Gross Profit:	$-1.87M (-2 834.85 %)
EPS:	$-1.100

Financial Reports:

No articles found.

Vaxxinity, Inc.

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.